What is ReposiTrak's latest dividend and current dividend yield?

Did ReposiTrak beat or miss consensus estimates last quarter?

What guidance did ReposiTrak's management provide for the next earnings period?

What is the revenue and EPS growth rate for ReposiTrak year over year?

What is the market's earnings forecast for ReposiTrak next quarter?

What factors drove the changes in ReposiTrak's revenue and profit?

What does ReposiTrak do and what are its main business segments?

What were the key takeaways from ReposiTrak's earnings call?

- **Revenue Growth & Cash Flow**: 7% revenue growth to $5.9M, net cash up 16% CAGR to $28.7M. Returned $2.2M to shareholders via buybacks.
- **AI-Driven Traceability**: 500+ anomaly detection algorithms auto-correct 90% of supplier errors, reducing customer costs by 50%.
- **FDA Deadline Catalyst**: 18-month countdown to 2028 compliance, with 70% of suppliers unprepared. Company expects Q4 2026 onboarding surge.
- **Cross-Selling Success**: 98% recurring revenue mix, cross-sell rate up 30% YoY across compliance, supply chain, and Traceability solutions.
- **Patent Moat**: 9 issued patents + 2 new filings protect Touchless Traceability IP, blocking competitors from copying core innovations.


**【CFO Financial Commentary】**
- Q2 2026 revenue grew 7% YoY to $5.9 million, driven by SaaS model expansion (98% recurring revenue). Operating expenses decreased 2% to $5.9 million, with SG&A up 5% due to higher commissions and benefits.
- GAAP net income rose 9% to $1.7 million, EPS increased 13% to $0.09. Year-to-date, net cash grew to $28.7 million, with $2.2 million in share buybacks and $750k in preferred stock redemptions.
- Company maintains 0 bank debt, returning 50% of cash flow to shareholders via buybacks and dividends (dividend up 10% annually since 2022).

**【CEO Business Strategy】**
- Traceability Network (RTN) leads industry with 2 million records, using AI to detect and auto-correct 500+ data anomalies. New Touchless Traceability专利 filings protect end-to-end solution, reducing supplier error rates from 50-70% to near-zero.
- Cross-selling success: all solutions share common platform, enabling efficient upselling. Q2 shows 8-10% of revenue from Traceability, up from 8% in FY25.
- FDA 2028 deadline accelerates demand, with 18 months remaining for suppliers to comply. Company expects acceleration in onboarding as 2026 progresses.

**【Q&A Highlights】**
- **Traceability Growth**: CEO estimates 8-10% of revenue from Traceability, up from 8% in FY25. AI-driven error correction reduces costs for growers/distributors by 50%+.
- **AI Impact**: Unlike LLMs, ReposiTrak's AI focuses on data validation, not content generation. System auto-corrects 90% of errors, saving customers $100k+ annually.
- **FDA Deadline Risk**: 70% of suppliers lack Traceability readiness. Company sees 24-36 month implementation timelines, vs. FDA's 18-month mandate.
- **M&A Strategy**: No active deals, focused on organic growth. CEO: "We have plenty to do with our own IP and pipeline."
- **Inflation Impact**: Short-term neutral, long-term risk if retailers face margin pressure and reduce IT spend.


ReposiTrak, Inc. (TRAK) Q2 2026 Earnings Call Transcript

- **Revenue Growth**: 10% YoY to $6 million, outpacing expenses and driving 28% operating profit growth.
- **Tax Rate Increase**: Effective rate to rise above 6% as NOLs expire, with $1.5 million cash flow from operations.
- **Automation Success**: AI reduces data errors by 70%, with Wizards handling 3,000+ daily tasks. The modernization project aims to embed AI in core systems, reducing costs and boosting scalability.
- **Market Expansion**: Traceability network growth and ingredient supplier participation expand addressable market, aligning with regulatory trends.
- **Shareholder Returns**: $1.8 million net income, 13% EPS growth, with $28.8 million cash on hand and no debt.

**【Management Opening Remarks】**
- Jeff Stanlis provided an overview of the call, emphasizing forward-looking statements and risks. The company issued a press release with financial highlights, available on their Investor Relations website.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q1 2026 revenue reached $6 million, a 10% year-over-year increase from $5.4 million.
- **Operating Expenses**: Total operating expenses rose 3%, driven by investments in AI tools, cybersecurity, and database fees. SG&A expenses increased 6% due to payroll and insurance costs.
- **Profitability**: Income from operations grew 28% to $1.9 million, with GAAP net income up 13% to $1.8 million. The effective tax rate is expected to rise above 6% as NOLs expire, with cash flow from operations at $1.5 million.
- **Capital Allocation**: The company returned 50% of free cash flow to shareholders, repurchasing 8,715 shares and redeeming $6.1 million in preferred stock. $7.8 million remains available for common share buybacks.

**【CEO Strategy & Automation】**
- **Automation & AI**: Randy Fields highlighted the use of Wizards (automated tools) to reduce data errors by 70%, with AI-driven error correction and cross-selling initiatives. The company is modernizing its development environment to embed AI analytics, aiming to scale without adding staff.
- **Traceability Network (RTN)**: The largest network in the industry, with 1 second of downtime in 7 years. Cross-selling compliance and supply chain solutions leverages a single platform, driving 30% net margins.

**【Q&A Highlights】**
- **Government Shutdown Impact**: Minimal disruption to the food industry, with cautious spending but no material impact on ReposiTrak's operations.
- **Market Expansion**: Ingredient suppliers joining RTN expand the addressable market, ensuring data integrity across the supply chain. This trend is expected to accelerate as regulatory compliance demands grow.


ReposiTrak, Inc. (TRAK) Q1 2026 Earnings Call Transcript

- **Revenue & Profit Growth**: 11% revenue growth, 17% net income increase, and 21% EPS rise highlight strong execution.
- **Deferred Revenue Surge**: 30% jump to $3.2 million signals future revenue strength.
- **Automation Expansion**: AI Wizard enables smaller customer onboarding, doubling addressable market.
- **Capital Return Focus**: $25M+ returned to shareholders, with 50% of cash flow allocated to buybacks/dividends.
- **Strategic Positioning**: Leading traceability network with cross-selling opportunities across compliance and supply chain.

**【CFO Financial Commentary】**
- **Revenue Growth**: Full year revenue increased 11% to $22.6 million, with recurring revenue at 98% of total. Q4 revenue rose 11% to $5.8 million.
- **Profitability**: GAAP net income grew 17% to $7 million, with EPS up 21% to $0.36. Cash from operations increased 21% to $8.4 million.
- **Deferred Revenue**: Rose 30% to $3.2 million, reflecting $800,000 in new contracts.
- **Cost Management**: Operating expenses grew 6%, but revenue outpaced costs by ~2x. Contribution margin target is 80%.
- **Capital Allocation**: Returned $25 million+ to shareholders via buybacks, preferred share redemptions, and dividends. 50% of cash flow is returned to investors.

**【CEO Summary】**
- **Automation Success**: AI-driven Wizard reduced onboarding costs, enabling expansion into smaller suppliers (e.g., $300k+ in setup fees vs. $95k prior).
- **Market Expansion**: Targeting middle-tier suppliers to push traceability compliance upstream and downstream, doubling addressable market.
- **Cross-Selling**: 98% of customers use a single platform, driving easy expansion into adjacent solutions (e.g., compliance, supply chain).
- **Network Effect**: Largest traceability network in the world, with FDA timeline extensions creating long-term growth opportunities.

**【Q&A Highlights】**
- **Tariffs Impact**: Minimal direct or indirect impact on business; retailers are absorbing costs.
- **M&A Strategy**: Open to accretive bolt-on acquisitions in adjacent industries, but no immediate plans.
- **Dividend Policy**: Prefer regular dividend increases over one-time payouts; dividend raised 3x in 2 years.
- **Crypto Treasury**: No plans; prioritize cash generation and balance sheet strength.

ReposiTrak, Inc. (TRAK) Q4 2025 Earnings Call Transcript

- **Revenue Acceleration**: 16% Q3 growth, 10% FYTD, driven by cross-selling and automated onboarding.
- **Profit Margin Expansion**: 27% net income growth, targeting 80% contribution margin from $0.50 currently.
- **Cash Machine**: $28M cash, returning 50% of $7M+ annual cash flow to shareholders.
- **Automation Edge**: 2/3 new traceability customers use Wizard, reducing costs and accelerating revenue.
- **Pipeline Expansion**: Developing recall management, forecasting, and supply chain adjacencies for higher-margin adjacencies.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue increased 16% YoY to $5.9 million, driven by cross-selling across traceability, supply chain, and compliance solutions.
- **Automation Efficiency**: 2/3 of new traceability customers onboard via automated Wizard, reducing human intervention and accelerating revenue recognition.
- **Customer-Centric Strategy**: Balancing 10-20% annual revenue growth with customer service, translating 16% revenue growth into 33% net income growth for common shareholders.
- **Future Product Pipeline**: Developing new solutions in recall management, ordering/forecasting, and supply chain adjacencies to leverage single-platform operating leverage.

**【CFO Financial Commentary】**
- **Profitability Metrics**: GAAP net income rose 27% YoY to $2 million, with $0.50 of every incremental revenue dollar flowing to the bottom line. Targeting 80% contribution margin vs. current 50%.
- **Cash Generation**: $28.1 million cash on hand (net of $25M+ returned to shareholders via dividends, buybacks, and preferred redemptions). FYTD cash from operations: $7 million.
- **Cost Structure**: Fixed costs (~$12M/year) include R&D, marketing, and operations. Variable costs (commissions, onboarding) expected to flatten as automation scales.
- **Capital Allocation**: 50% of annual cash flow returned to shareholders (dividends, buybacks), 50% retained for growth and balance sheet strength.

**【Q&A Key Takeaways】**
- **Tariffs Impact**: Minimal direct impact; uncertainty may slow industry decision-making but not ReposiTrak's growth trajectory.
- **Cross-Selling Success**: 98% recurring revenue mix reflects deep customer relationships and platform interoperability. New customers often expand to 2-3 services within 12 months.
- **M&A Strategy**: Prefer organic development (6-12 month build times) over acquisitions. Open to partnerships for domain expertise or customer access, but no active deals.
- **Tax Outlook**: ~$8-9M remaining net operating losses. Future tax rate TBD but expected to rise from current ~0% effective rate.


ReposiTrak, Inc. (TRAK) Q3 2025 Earnings Call Transcript

- **Revenue Growth Accelerating**: Q2 revenue up 7% to $5.5M, with deferred revenue surging 70% to $4.2M, enabling $1.7M annualized incremental revenue.
- **Cash Flow Strength**: $28M cash on hand, 117% YoY growth in operating cash flow, and no debt.
- **Traceability Leadership**: Largest traceability network with 5,500 facilities in pipeline, targeting 10-20% FY25 growth.
- **Automation & Efficiency**: Wizard platform reducing onboarding costs, with 60-70% of customers expected to onboard independently by end-2025.
- **FDA Delay Opportunity**: Anticipated enforcement delay supports smoother customer adoption and higher profitability.

**【CFO Financial Commentary】**
- **Q2 2025 Financial Highlights**: Total revenue increased 7% to $5.5 million, with recurring revenue at $5.4 million. GAAP net income rose 7% to $1.6 million, and EPS grew 14% to $0.08. Year-to-date, net income climbed 14% to $3.2 million.
- **Deferred Revenue Growth**: Deferred revenue surged 70% YoY to $4.2 million, translating to $1.7 million in incremental annualized revenue. This growth is expected to drive QoQ revenue increases of ~$425,000.
- **Cash Flow Strength**: Cash on hand reached $28 million, up 12% from June 2024, with operating cash flow up 117% YoY. The company redeemed $1.5 million in preferred shares and maintained no bank debt.

**【CEO Strategic Overview】**
- **Traceability Momentum**: The company is the largest traceability network, with 5,500 facilities in onboarding pipeline, representing $10 million in potential annualized revenue. The FDA's January 2026 deadline is expected to delay enforcement, allowing smoother customer onboarding.
- **Cross-Selling Success**: Customers expanding compliance business also increase traceability usage, driving double-digit growth in both segments. For example, one customer doubled compliance scope after successful traceability implementation.
- **Partnerships & Network Effects**: Partnerships like Upshop leverage ReposiTrak's universal data translation capabilities, attracting additional retailers and suppliers. This network effect is expected to accelerate growth in the second half of 2025.

**【Q&A Key Takeaways】**
- **Customer Onboarding Automation**: The Wizard platform now handles a growing share of onboarding, with 60-70% of customers expected to onboard independently within a year. This reduces costs and improves scalability.
- **Cost Structure Efficiency**: Fixed cash costs remain at $12 million, with minimal incremental expenses for new revenue. Contribution margin target is 80%, up from current 64%.
- **Industry Trends & Risks**: Slow FDA enforcement is seen as beneficial, while egg shortages and tariffs are transient issues. The company is not directly impacted by AI trends but uses AI internally for efficiency.

Actual											0.01	0.02	0.02	0.08	0.03	0.05	0.04	0.04	0.05	0.05	0.06	0.06	0.08	0.07	0.07	0.07	0.08	0.08	0.08	0.08	0.1	0.09	0.09	0.09
Forecast											0.03	0.01	0.02	0.035	0.04	0.06	0.05	0.04	0.05	0.05	0.06	0.06	0.07	0.07	0.07	0.06	0.11	0.06	0.08	0.0887	0.09	0.09	0.09	0.09
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-66.67%	+100.00%	0.00%	+128.57%	-25.00%	-16.67%	-20.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+14.29%	0.00%	0.00%	+16.67%	-27.27%	+33.33%	0.00%	-9.81%	+11.11%	0.00%	0.00%	0.00%

TRAK

TRAK fundamentals

TRAK Q2 2026 Earnings

Earnings Call

You can ask Aime

TRAK

TRAK fundamentals

TRAK Q2 2026 Earnings

Earnings Call

TRAK Earnings Call Summary for Q2/20264:15 PM on Feb 17, 2026

TRAK Earnings Call Summary for Q1/20264:15 PM on Nov 13, 2025

TRAK Earnings Call Summary for Q4/20254:15 PM on Sep 29, 2025

TRAK Earnings Call Summary for Q3/20254:15 PM on May 15, 2025

TRAK Earnings Call Summary for Q2/20254:15 PM on Feb 12, 2025

You can ask Aime